Clinical Trial

Targeting Reactive Oxygen Species Production as a Novel Therapeutic in Fuch's Endothelial Corneal Dystrophy

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated September 29, 2025 (before its estimated April 29, 2026 completion). Its status may not reflect the trial's current state.
Summary
This protocol will investigate whether topical application of N-acetyl cysteine (NAC) eye drops decreases oxidative stress and confers cytoprotection in patients with FECD.
Protocol Amendment History 7 amendments
This ClinicalTrials.gov record has been amended 7 times since 2020-06-17; most recent amendment 2025-09-23.
Status change: Not Yet Recruiting → Recruiting 2020-11-03
Trial Details
NCT Number NCT04440280
Lead Sponsor Massachusetts Eye and Ear Infirmary
Conditions Fuchs Endothelial Corneal Dystrophy
Enrollment 45 participants
Start Date 2020-09-16
Primary Completion 2026-04-29 (estimated)
Study Completion 2027-04-30 (estimated)
Updated on ClinicalTrials.gov 2025-09-29